78.4 F
San Fernando
Wednesday, Jul 24, 2024

Approval of Medtronic’s Insulin Pump

A new insulin pump system from Medtronic, named the Minimed 770G, has received approval from the U.S. Food and Drug Administration as of early September. The medical device company is headquartered in Dublin, but its diabetes division operates out of Northridge. The company’s latest insulin pump is available to children as young as 2 years old with Type 1 diabetes, and offers users the technology to see pump data in real time. The system can also send data to clinicians and educators if needed. “We’re thrilled to be launching this new system as we understand how important these data-sharing features are, particularly right now — with many individuals and families opting to see their doctors virtually via telehealth visits,” Sean Salmon, vice president of Medtronic Diabetes Group, said in a statement. Also, the 770G’s SmartGuard technology connects the device with the user’s smartphone, and continually adjusts the amount of insulin delivery every five minutes, Medtronic said in a statement. “I have seen favorable results with the MiniMed 670G system in my practice, and the younger age indication that the MiniMed 770G system offers can change the lives of even more people living with Type 1 diabetes,” Dr. Jennifer McVean, pediatric endocrinologist with the University of Minnesota Health, said in a statement. “When young children are diagnosed with diabetes, it is a family disease with parents and caregivers playing a substantial role in diabetes management.” Any future software updates can be done right on the phone too, through SmartGuard. Medtronic said the feature enables enhanced security over time. Medtronic began taking orders for the MiniMed 770G in the United States the first week of September, the company said.

Featured Articles

Related Articles